Invited commentary: Influenza vaccine and guillain-barré syndrome-is there a risk?

Research output: Contribution to journalArticle

Abstract

After a new reassortant swine influenza A H1N1 virus caused outbreaks in Mexico and the United States in 2009, a vaccine was prepared from this virus to immunize the entire US population. Surveillance for Guillain-Barré syndrome (GBS) after receipt of this vaccine was carried out in 3 populations: the Vaccine Safety Datalink Project, the 10 Centers for Disease Control and Prevention Emerging Infections Program sites, and a network of large insurance companies. These studies found a small increase of approximately 1 case of GBS per million vaccinees above the baseline rate, which is similar to that observed after administration of seasonal influenza vaccines over the past several years. Enhanced surveillance for GBS was conducted in 2009-2010 because of the experience in 1976 of 362 GBS cases' occurring during the 6 weeks after influenza vaccination of 45 million persons, an 8.8-fold increase over background rates. The 1976 mass immunization had been conducted to prevent an influenza epidemic from another swine influenza A H1N1 recombinant virus. It can be concluded from these recent studies that influenza vaccination overall is of public health benefit, helping to reduce mortality and prevent the thousands of deaths that occur from annual seasonal influenza outbreaks, despite the possibility of a small increased risk of GBS associated with influenza vaccines.

Original languageEnglish (US)
Pages (from-to)1129-1132
Number of pages4
JournalAmerican Journal of Epidemiology
Volume175
Issue number11
DOIs
StatePublished - Jun 2012

Fingerprint

Influenza Vaccines
Human Influenza
H1N1 Subtype Influenza A Virus
Vaccines
Disease Outbreaks
Vaccination
Swine
Mass Vaccination
Influenza A virus
Insurance Benefits
Centers for Disease Control and Prevention (U.S.)
Mexico
Insurance
Population
Public Health
Viruses
Safety
Mortality
Infection

Keywords

  • Guillain-Barre syndrome
  • H1N1 subtype
  • influenza A virus
  • influenza vaccines
  • population surveillance
  • safety
  • vaccines

ASJC Scopus subject areas

  • Epidemiology

Cite this

Invited commentary : Influenza vaccine and guillain-barré syndrome-is there a risk? / Nelson, Kenrad Edwin.

In: American Journal of Epidemiology, Vol. 175, No. 11, 06.2012, p. 1129-1132.

Research output: Contribution to journalArticle

@article{a31e52282ebb471a922fc6d3ce9c6d74,
title = "Invited commentary: Influenza vaccine and guillain-barr{\'e} syndrome-is there a risk?",
abstract = "After a new reassortant swine influenza A H1N1 virus caused outbreaks in Mexico and the United States in 2009, a vaccine was prepared from this virus to immunize the entire US population. Surveillance for Guillain-Barr{\'e} syndrome (GBS) after receipt of this vaccine was carried out in 3 populations: the Vaccine Safety Datalink Project, the 10 Centers for Disease Control and Prevention Emerging Infections Program sites, and a network of large insurance companies. These studies found a small increase of approximately 1 case of GBS per million vaccinees above the baseline rate, which is similar to that observed after administration of seasonal influenza vaccines over the past several years. Enhanced surveillance for GBS was conducted in 2009-2010 because of the experience in 1976 of 362 GBS cases' occurring during the 6 weeks after influenza vaccination of 45 million persons, an 8.8-fold increase over background rates. The 1976 mass immunization had been conducted to prevent an influenza epidemic from another swine influenza A H1N1 recombinant virus. It can be concluded from these recent studies that influenza vaccination overall is of public health benefit, helping to reduce mortality and prevent the thousands of deaths that occur from annual seasonal influenza outbreaks, despite the possibility of a small increased risk of GBS associated with influenza vaccines.",
keywords = "Guillain-Barre syndrome, H1N1 subtype, influenza A virus, influenza vaccines, population surveillance, safety, vaccines",
author = "Nelson, {Kenrad Edwin}",
year = "2012",
month = "6",
doi = "10.1093/aje/kws194",
language = "English (US)",
volume = "175",
pages = "1129--1132",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Invited commentary

T2 - Influenza vaccine and guillain-barré syndrome-is there a risk?

AU - Nelson, Kenrad Edwin

PY - 2012/6

Y1 - 2012/6

N2 - After a new reassortant swine influenza A H1N1 virus caused outbreaks in Mexico and the United States in 2009, a vaccine was prepared from this virus to immunize the entire US population. Surveillance for Guillain-Barré syndrome (GBS) after receipt of this vaccine was carried out in 3 populations: the Vaccine Safety Datalink Project, the 10 Centers for Disease Control and Prevention Emerging Infections Program sites, and a network of large insurance companies. These studies found a small increase of approximately 1 case of GBS per million vaccinees above the baseline rate, which is similar to that observed after administration of seasonal influenza vaccines over the past several years. Enhanced surveillance for GBS was conducted in 2009-2010 because of the experience in 1976 of 362 GBS cases' occurring during the 6 weeks after influenza vaccination of 45 million persons, an 8.8-fold increase over background rates. The 1976 mass immunization had been conducted to prevent an influenza epidemic from another swine influenza A H1N1 recombinant virus. It can be concluded from these recent studies that influenza vaccination overall is of public health benefit, helping to reduce mortality and prevent the thousands of deaths that occur from annual seasonal influenza outbreaks, despite the possibility of a small increased risk of GBS associated with influenza vaccines.

AB - After a new reassortant swine influenza A H1N1 virus caused outbreaks in Mexico and the United States in 2009, a vaccine was prepared from this virus to immunize the entire US population. Surveillance for Guillain-Barré syndrome (GBS) after receipt of this vaccine was carried out in 3 populations: the Vaccine Safety Datalink Project, the 10 Centers for Disease Control and Prevention Emerging Infections Program sites, and a network of large insurance companies. These studies found a small increase of approximately 1 case of GBS per million vaccinees above the baseline rate, which is similar to that observed after administration of seasonal influenza vaccines over the past several years. Enhanced surveillance for GBS was conducted in 2009-2010 because of the experience in 1976 of 362 GBS cases' occurring during the 6 weeks after influenza vaccination of 45 million persons, an 8.8-fold increase over background rates. The 1976 mass immunization had been conducted to prevent an influenza epidemic from another swine influenza A H1N1 recombinant virus. It can be concluded from these recent studies that influenza vaccination overall is of public health benefit, helping to reduce mortality and prevent the thousands of deaths that occur from annual seasonal influenza outbreaks, despite the possibility of a small increased risk of GBS associated with influenza vaccines.

KW - Guillain-Barre syndrome

KW - H1N1 subtype

KW - influenza A virus

KW - influenza vaccines

KW - population surveillance

KW - safety

KW - vaccines

UR - http://www.scopus.com/inward/record.url?scp=84862180260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862180260&partnerID=8YFLogxK

U2 - 10.1093/aje/kws194

DO - 10.1093/aje/kws194

M3 - Article

C2 - 22582208

AN - SCOPUS:84862180260

VL - 175

SP - 1129

EP - 1132

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 11

ER -